For instance, Vemurafenib (BRAF inhibitor) elicited only a 5% response rate in BRAF-mutant CRC patients in contrast to dramatic responses seen in BRAF-mutant melanoma patients [37]. This evidence concerns the gene BRAF and colorectal carcinoma.